Overview
- A CDC surveillance report shows clinical Candida auris infections climbed from 2,882 in 2022 to 6,197 in 2024 and bloodstream cases rose about 60 percent to 1,586, indicating more invasive disease as well as more detections.
- Part of the increase reflects expanded testing and screening programs and the 2023 decision to make screening detections nationally notifiable, which raised counts independent of transmission.
- Nearly every Candida auris isolate is resistant to fluconazole, and the surveillance data do not include lab susceptibility results needed to measure trends in echinocandin resistance or pan‑resistant strains.
- Hospitals shifted where they screen for the yeast, with long‑term acute care facilities falling from a majority of screening detections to 36 percent and ordinary acute care hospitals rising to about half as admission screening expanded.
- Year‑over‑year growth has slowed, a change the CDC links to restored infection‑control practices; the report makes clear that sustained screening, better lab susceptibility reporting, and routine hygiene are key to protecting fragile, hospitalized patients.